EP1263452A4 - Methods and compositions for generating angiostatin - Google Patents

Methods and compositions for generating angiostatin

Info

Publication number
EP1263452A4
EP1263452A4 EP01907105A EP01907105A EP1263452A4 EP 1263452 A4 EP1263452 A4 EP 1263452A4 EP 01907105 A EP01907105 A EP 01907105A EP 01907105 A EP01907105 A EP 01907105A EP 1263452 A4 EP1263452 A4 EP 1263452A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
angiostatin
generating
generating angiostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01907105A
Other languages
German (de)
French (fr)
Other versions
EP1263452A2 (en
Inventor
Gerald Soff
Stephen T Gately
Przemyslaw Twardowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of EP1263452A2 publication Critical patent/EP1263452A2/en
Publication of EP1263452A4 publication Critical patent/EP1263452A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
EP01907105A 2000-02-08 2001-02-08 Methods and compositions for generating angiostatin Withdrawn EP1263452A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50039700A 2000-02-08 2000-02-08
US500397 2000-02-08
PCT/US2001/004021 WO2001058921A2 (en) 2000-02-08 2001-02-08 Methods and compositions for generating angiostatin

Publications (2)

Publication Number Publication Date
EP1263452A2 EP1263452A2 (en) 2002-12-11
EP1263452A4 true EP1263452A4 (en) 2006-12-20

Family

ID=23989238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01907105A Withdrawn EP1263452A4 (en) 2000-02-08 2001-02-08 Methods and compositions for generating angiostatin

Country Status (5)

Country Link
EP (1) EP1263452A4 (en)
JP (1) JP2004508006A (en)
AU (1) AU2001234926A1 (en)
CA (1) CA2400497A1 (en)
WO (1) WO2001058921A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000475A (en) 2009-07-10 2012-03-26 Thrombogenics Nv Variants of plasminogen and plasmin.
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN103764163A (en) 2011-08-12 2014-04-30 斯路姆基因公司 Plasminogen and plasmin variants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003030A1 (en) * 1986-10-31 1988-05-05 Moscatelli David A METHOD FOR INDUCING ENDOGENOUS PRODUCTION OF TISSUE PLASMINOGEN ACTIVATOR (tPA)
EP0366033A2 (en) * 1988-10-24 1990-05-02 E.R. SQUIBB & SONS, INC. Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination
WO1998015574A1 (en) * 1996-09-17 1998-04-16 Northwestern University Methods and compositions for generating angiostatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003030A1 (en) * 1986-10-31 1988-05-05 Moscatelli David A METHOD FOR INDUCING ENDOGENOUS PRODUCTION OF TISSUE PLASMINOGEN ACTIVATOR (tPA)
EP0366033A2 (en) * 1988-10-24 1990-05-02 E.R. SQUIBB & SONS, INC. Method of improving post-ischemic myocardial dysfunction using an ace inhibitor alone or in combination with a thrombolytic agent and combination
WO1998015574A1 (en) * 1996-09-17 1998-04-16 Northwestern University Methods and compositions for generating angiostatin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRIESS ET AL: "Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 113, no. 3, September 1997 (1997-09-01), pages 904 - 913, XP005688578, ISSN: 0016-5085 *
HOURANI B T ET AL: "INHIBITION OF S-91 MOUSE MELANOMA METASTASES AND GROWTH BY D-PENICILLAMINE", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 21, no. 5, 1969, pages 434 - 438, XP008010946, ISSN: 0023-6837 *
See also references of WO0158921A3 *
VOLPERT O V ET AL: "Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 3, 1 August 1996 (1996-08-01), pages 671 - 679, XP002223374, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2001058921A3 (en) 2002-02-14
WO2001058921A9 (en) 2002-03-14
JP2004508006A (en) 2004-03-18
WO2001058921A2 (en) 2001-08-16
AU2001234926A1 (en) 2001-08-20
EP1263452A2 (en) 2002-12-11
CA2400497A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
IL151781A0 (en) Methods and compositions for rna interference
AU8911801A (en) Improved nanocomposite compositions and methods for making and using same
PL351552A1 (en) Gypsum compositions and related methods
EP1421117A4 (en) Compositions and methods for generating chimeric heteromultimers
AU2002357119A8 (en) Mitocidal compositions and methods
AU2001268627A1 (en) Compositions and methods for generating expression vectors through site-specificrecombination
AU4570901A (en) Biocidal methods and compositions
AU6832101A (en) Composition and method
EP1313477A4 (en) Compounds and methods
AU4163402A (en) Composition and method
AU4215501A (en) Plant acaricidal compositions and methods
EP1274424A4 (en) Compounds and methods
AU8852301A (en) Compositions and methods for inducing vasorelaxation
AU4215901A (en) Methods and compositions for immunoregulation
ZA200302014B (en) Methods and compositions for promoting the maturation of monocytes.
IL154267A0 (en) Neuroprotective 2-pyridinamine compositions and related methods
AU2002357748A8 (en) Osteopontin-related compositions and methods
GB0014975D0 (en) Waco
PL360243A1 (en) Benzoxazepinones and their use as squalene synthase inhibitors
EP1277459A4 (en) Perming compositions and perming method by using the same
EP1263452A4 (en) Methods and compositions for generating angiostatin
AU3957202A (en) Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
AU1182402A (en) Methods and compositions for enhancing angiogenesis
EP1343796A4 (en) Compounds and methods
GB2378135B (en) Compositions derived from modiolus modiolus and methods for making and using same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020806

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TWARDOWSKI, PRZEMYSLAW

Inventor name: SOFF, GERALD

Inventor name: GATELY, STEPHEN, T.

A4 Supplementary search report drawn up and despatched

Effective date: 20061120

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOFF, GERALD

Inventor name: GATELY, STEPHEN, T.

Inventor name: TWARDOWSKI, PRZEMYSLAW

17Q First examination report despatched

Effective date: 20070726

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090609